
Investors Target Beta Bionics Over Concealed Safety Complaints
A federal securities class action now challenges Beta Bionics, alleging the medical device manufacturer misled shareholders by suppressing thousands of safety reports. While management publicly touted the ease of its iLet insulin system, internal records reportedly reveal a pattern of ignored malfunctions and life-threatening hypoglycemic events kept hidden from the public.
























